<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39376422</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2231-3796</ISSN><JournalIssue CitedMedium="Print"><Volume>76</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India</Title><ISOAbbreviation>Indian J Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Dependability and Prognostic Value of Biomarkers in COVID-19 Associated Rhino-Orbito- Cerebral Mucormycosis- A Long Term Ambispective Study.</ArticleTitle><Pagination><StartPage>4559</StartPage><EndPage>4568</EndPage><MedlinePgn>4559-4568</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12070-024-04921-3</ELocationID><Abstract><AbstractText Label="UNLABELLED">COVID-19 pandemic, which has exhibited a wide clinical spectrum and an unexpected surge in mucormycosis cases, understanding various biomarkers' roles becomes pivotal. As mucormycosis leads to clinical morbidity and mortality through angioinvasion and thromboembolism, unveiling the correlation between these markers and disease progression can shed light on the reasons behind mucormycosis's emergence as an epidemic, especially following the second wave of COVID-19. This long term ambispective observational study, conducted from May 2020 to July 2023, aimed to assess specific biomarkers as predictors of severity in COVID-19-associated mucormycosis (CAM). Biomarkers measured included ESR, CRP, D-dimer, IL-8, PCT, serum ferritin, and neutrophil-lymphocyte ratio (NLR) at different time points. Data analysis employed descriptive statistics, repeated measure ANOVA, Spearman correlations, ROC curve analysis, and logistic regression. Of 290 patients, 198 completed the 2-year follow-up. Elevated baseline biomarker levels significantly decreased with treatment initiation. CRP and NLR emerged as significant predictors of severe CAM, with odds ratio 2.926 (95% CI 1.466-4.360) and 2.203 (95% CI 0.863-1.040) respectively. Factors influencing CAM progression included age, CRP, and NLR, while all biomarkers independently predicted mortality. A death prediction model using CRP, PCT, D-dimer, NLR, and IL-8 demonstrated exceptional performance, with a sensitivity of 83.1% and specificity of 100%. Elevated inflammatory markers in CAM patients showed a decline with treatment, with NLR and CRP proving crucial for predicting severity. Serial monitoring of IL-8, CRP, PCT, NLR, D-dimer, and ferritin provides insights into disease progression and prognosis. The study underscores the importance of biomarker assessment in managing CAM, especially in the context of the unpredictable clinical spectrum of COVID-19 and the subsequent mucormycosis surge.</AbstractText><AbstractText Label="SUPPLEMENTARY INFORMATION" NlmCategory="UNASSIGNED">The online version contains supplementary material available at 10.1007/s12070-024-04921-3.</AbstractText><CopyrightInformation>© Association of Otolaryngologists of India 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Das</LastName><ForeName>K Nidhin</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, All India Institute of Medical Sciences, Jodhpur, India.</Affiliation><Identifier Source="GRID">grid.413618.9</Identifier><Identifier Source="ISNI">0000 0004 1767 6103</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Diksha</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, All India Institute of Medical Sciences, Jodhpur, India.</Affiliation><Identifier Source="GRID">grid.413618.9</Identifier><Identifier Source="ISNI">0000 0004 1767 6103</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Vidhu</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, All India Institute of Medical Sciences, Jodhpur, India.</Affiliation><Identifier Source="GRID">grid.413618.9</Identifier><Identifier Source="ISNI">0000 0004 1767 6103</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soni</LastName><ForeName>Kapil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, All India Institute of Medical Sciences, Jodhpur, India.</Affiliation><Identifier Source="GRID">grid.413618.9</Identifier><Identifier Source="ISNI">0000 0004 1767 6103</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Mithu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, India.</Affiliation><Identifier Source="GRID">grid.413618.9</Identifier><Identifier Source="ISNI">0000 0004 1767 6103</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhury</LastName><ForeName>Bikram</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, All India Institute of Medical Sciences, Jodhpur, India.</Affiliation><Identifier Source="GRID">grid.413618.9</Identifier><Identifier Source="ISNI">0000 0004 1767 6103</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Amit</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4339-7541</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, All India Institute of Medical Sciences, Jodhpur, India.</Affiliation><Identifier Source="GRID">grid.413618.9</Identifier><Identifier Source="ISNI">0000 0004 1767 6103</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>9422551</NlmUniqueID><ISSNLinking>2231-3796</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">COVID-19 associated mucormycosis</Keyword><Keyword MajorTopicYN="N">Inflammatory markers</Keyword><Keyword MajorTopicYN="N">Long term outcomes of mucormycosis</Keyword></KeywordList><CoiStatement>Competing InterestsAll authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39376422</ArticleId><ArticleId IdType="pmc">PMC11456141</ArticleId><ArticleId IdType="doi">10.1007/s12070-024-04921-3</ArticleId><ArticleId IdType="pii">4921</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux JP et al (2022) The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe 3(7):e543–e552</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8789240</ArticleId><ArticleId IdType="pubmed">35098179</ArticleId></ArticleIdList></Reference><Reference><Citation>Radotra B, Challa S (2022) Pathogenesis and Pathology of COVID-Associated Mucormycosis: what is New and why. Curr Fungal Infect Rep 16(4):206–220</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9520103</ArticleId><ArticleId IdType="pubmed">36193101</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A, So M, Mitaka H, Ishisaka Y, Takagi H, Inokuchi R et al (2022) Clinical features and mortality of COVID-19-Associated mucormycosis: a systematic review and Meta-analysis. Mycopathologia 187(2–3):271–289</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935886</ArticleId><ArticleId IdType="pubmed">35312945</ArticleId></ArticleIdList></Reference><Reference><Citation>Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R (2021) Epidemiology and pathophysiology of COVID-19-Associated mucormycosis: India Versus the Rest of the World. Mycopathologia 186(6):739–754</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8375614</ArticleId><ArticleId IdType="pubmed">34414555</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghazi BK, Zahid U, Usman MA, Kazmi Z, Hunain R, Riaz MMA et al (2022) Antifungal drugs shortage in India amidst looming increase in Invasive Fungal infections among COVID-19 patients: an Impending Crisis. Innov Pharm 13(2). 10.24926/iip.v13i2.4480</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9836748</ArticleId><ArticleId IdType="pubmed">36654706</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayak PS, Katyal I, Kumar AD, Prasheetha B, Harugop AS, Reshma R (2022) COVID 19 Associated Mucormycosis: preventable risk factors leading to a better prognosis: a Case Series. Indian J Otolaryngol Head Neck Surg 74(Suppl 2):3536–3540</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9486771</ArticleId><ArticleId IdType="pubmed">36160947</ArticleId></ArticleIdList></Reference><Reference><Citation>Shete A, Deshpande S, Sawant J, Warthe N, Thakar M, Madkaikar M et al (2023) Higher proinflammatory responses possibly contributing to suppressed cytotoxicity in patients with COVID-19 associated mucormycosis. Immunobiology 228(3):152384</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10089671</ArticleId><ArticleId IdType="pubmed">37071959</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav T, Tiwari S, Gupta A, Garg PK, Khera PS, Rajagopal R et al (2022) Magnetic resonance imaging in Coronavirus Disease – 2019 Associated Rhino-Orbital-Cerebral mucormycosis (CA-ROCM) - imaging analysis of 50 consecutive patients. Curr Probl Diagn Radiol 51(1):112–120</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8564981</ArticleId><ArticleId IdType="pubmed">34802841</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai N, Pradhan V, Chougule D, Tiwari S, Mandke C, Yadav RM et al (2023) Perturbations of immune landscape in COVID-19 associated mucormycosis. Mycoses 66(3):226–236</Citation><ArticleIdList><ArticleId IdType="pubmed">36380699</ArticleId></ArticleIdList></Reference><Reference><Citation>Dave TV, Nair AG, Joseph J, Freitag SK (2022) Immunopathology of COVID-19 and its implications in the development of rhino-orbital-cerebral mucormycosis: a major review. Orbit 41(6):670–679</Citation><ArticleIdList><ArticleId IdType="pubmed">35856238</ArticleId></ArticleIdList></Reference><Reference><Citation>Stringer D, Braude P, Myint PK, Evans L, Collins JT, Verduri A et al (2021) The role of C-reactive protein as a prognostic marker in COVID-19. Int J Epidemiol 50(2):420–429</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989395</ArticleId><ArticleId IdType="pubmed">33683344</ArticleId></ArticleIdList></Reference><Reference><Citation>RajS P, Godse A, P AM (2022) Role of inflammatory markers as prognostic indicators in treatment of Mucormycosis. Bengal J Otolaryngol Head Neck Surg 30(2):227–232</Citation></Reference><Reference><Citation>Maruna P, Nedelníková K, Gürlich R (2000) Physiology and genetics of procalcitonin. Physiol Res 49(Suppl 1):S57–61</Citation><ArticleIdList><ArticleId IdType="pubmed">10984072</ArticleId></ArticleIdList></Reference><Reference><Citation>Yh D, Jk D, Hl L, Xd S The role of procalcitonin in the identification of invasive fungal infection-a systemic review and meta-analysis. Diagnostic microbiology and infectious disease [Internet]. 2013 Aug [cited 2023 Oct 10];76(4). https://pubmed.ncbi.nlm.nih.gov/23711529/</Citation><ArticleIdList><ArticleId IdType="pubmed">23711529</ArticleId></ArticleIdList></Reference><Reference><Citation>Roques M, Chretien ML, Favennec C, Lafon I, Ferrant E, Legouge C et al (2016) Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis. Mycoses 59(6):383–390</Citation><ArticleIdList><ArticleId IdType="pubmed">26931315</ArticleId></ArticleIdList></Reference><Reference><Citation>Farghly Youssif S, Abdelrady MM, Thabet AA, Abdelhamed MA, Gad MOA, Abu-Elfatth AM et al (2022) COVID-19 associated mucormycosis in Assiut University Hospitals: a multidisciplinary dilemma. Sci Rep 12:10494</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212202</ArticleId><ArticleId IdType="pubmed">35729170</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao P, Rangankar V, Rohatgi S, Dubey P, Gitay A, Singh A et al (2023) Predictors of disease severity in COVID-19 associated mucormycosis: impact of HbA1C levels, time lag to mucormycosis onset, and radiologic patterns of paranasal sinuses and spaces involvement. Infect Dis (Lond) 55(11):755–766</Citation><ArticleIdList><ArticleId IdType="pubmed">37480325</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C et al (2020) Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 18(1):206</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237880</ArticleId><ArticleId IdType="pubmed">32434518</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbanowicz T, Michalak M, Olasińska-Wiśniewska A, Perek B, Rodzki M, Wachowiak-Baszyńska H et al (2021) Neutrophile-to-lymphocyte ratio as a predictor of mortality and response to treatment in invasive aspergillosis among Heart Transplant recipients—exploratory study. Med (Kaunas) 57(12):1300</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8703887</ArticleId><ArticleId IdType="pubmed">34946245</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Vidal C, Viasus D, Carratalà J (2013) Pathogenesis of invasive fungal infections. Curr Opin Infect Dis 26(3):270</Citation><ArticleIdList><ArticleId IdType="pubmed">23449139</ArticleId></ArticleIdList></Reference><Reference><Citation>Camargo JF, Husain S (2014) Immune correlates of Protection in Human Invasive aspergillosis. Clin Infect Dis 59(4):569–577</Citation><ArticleIdList><ArticleId IdType="pubmed">24803380</ArticleId></ArticleIdList></Reference><Reference><Citation>Winn RM, Gil-Lamaignere C, Roilides E, Simitsopoulou M, Lyman CA, Maloukou A et al (2003) Selective effects of Interleukin (IL)–15 on antifungal activity and IL-8 release by Polymorphonuclear Leukocytes in response to Hyphae of Aspergillus Species. J Infect Dis 188(4):585–590</Citation><ArticleIdList><ArticleId IdType="pubmed">12898448</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawlings SA, Heldt S, Prattes J, Eigl S, Jenks JD, Flick H et al (2019) Using Interleukin 6 and 8 in Blood and Bronchoalveolar Lavage Fluid to Predict Survival in Hematological Malignancy Patients With Suspected Pulmonary Mold Infection. Frontiers in Immunology [Internet]. [cited 2023 Oct 11];10. https://www.frontiersin.org/articles/10.3389/fimmu.2019.01798</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687868</ArticleId><ArticleId IdType="pubmed">31428097</ArticleId></ArticleIdList></Reference><Reference><Citation>Zirpe K, Pote P, Deshmukh A, Gurav SK, Tiwari AM, Suryawanshi P A retrospective analysis of risk factors of COVID-19 Associated Mucormycosis and Mortality predictors: a single-center study. Cureus 13(10):e18718</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8584128</ArticleId><ArticleId IdType="pubmed">34790473</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>